Chronic kidney disease (CKD) and microalbuminuria are associated with incident heart failure (HF), but their relative contributions to HF with preserved vs. reduced EF (HFpEF and HFrEF) are unknown. We sought to evaluate the associations of CKD and microalbuminuria with incident HF subtypes in the community-based Framingham Heart Study (FHS 
Introduction
Kidney disease is associated with poor heart failure (HF)-related outcomes regardless of disease severity. In patients with established HF, reduced estimated glomerular filtration rate (eGFR) and albuminuria are independent predictors of HF progression and mortality.
1 -6 Similarly, in community-based investigations, albuminuria and lower eGFR are associated with new-onset HF. 7 -13 The mechanisms responsible for cardiorenal interactions in HF are incompletely understood and are likely to vary by underlying disease process and HF syndrome.
14,15
Heart failure with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) represent separate clinical subtypes, each accounting for approximately half of HF diagnoses.
16 -20 Although controversy exists regarding whether HFpEF and HFrEF represent overlapping or distinct pathophysiological entities, 21, 22 substantial evidence supports distinct risk factor profiles 23 -25 and treatment responses 26 for each subtype. Therefore, understanding how specific risk factors relate to the development of HFpEF vs. HFrEF may allow for improved methods to predict, and potentially prevent, the occurrence of HF.
The relative contribution of kidney dysfunction to the development of HFpEF vs. HFrEF is not well elucidated. Incident HF subtypes have been adjudicated among participants of the Framingham Heart Study (FHS), where kidney function has also been systematically assessed. We sought to evaluate the associations of albuminuria and reduced glomerular filtration with incident HFpEF and HFrEF prospectively. To understand further the mechanisms underlying these associations, we investigated the cross-sectional relationships of albuminuria and reduced glomerular filtration with echocardiographic measures of cardiac structure and function.
Methods

Study samples
The design and enrolment of the FHS Original and Offspring cohorts have been detailed previously. 27, 28 Participants underwent comprehensive evaluation at the FHS clinic every 2 years (Original cohort) or 4 years (Offspring cohort). At each examination cycle, a comprehensive medical history, anthropometry, a cardiovascular-targeted physical examination, and ECG were performed.
To evaluate the associations of reduced eGFR and incident HF, we included Original cohort participants who attended examinations 15 (1977-1979) or 24 (1995-1998) , or Offspring cohort participants who attended examinations 2 (1979-1983) or 6 (1995-1998) . Follow-up was censored at 15 years or the date of the next examination, depending on which was the shorter follow-up time period. Participants in each cohort were eligible for inclusion at both examination cycles if no interim HF event occurred. 29 Of 10 858 eligible person-observations, we excluded 1 for missing follow-up time, 257 for off-site visits, 548 for missing clinical covariates, 108 for prevalent HF, and 55 for eGFR <15 mL/min/1.73 m 2 or for being on haemodialysis, yielding a final sample of 9889 person-observations. Urinary albumin and creatinine measures, and transthoracic echocardiography were performed at Offspring examination 6 
Laboratory measures
Fasting plasma samples were collected from FHS participants at each examination cycle, centrifuged, and stored at −80 ∘ C. Serum creatinine levels were assayed using the modified Jaffé method on a Roche Hitachi 911 (Roche Diagnostics), and eGFR was calculated using the CKD-EPI equation. 30 Chronic kidney disease (CKD) was defined as eGFR <60 mL/min/1.73 m 2 . Spot urine samples were collected at the sixth offspring examination cycle and stored at −20 ∘ C. Urine albumin concentration was assayed using immunoturbimetry (Tina Quant Albumin Assay, Roche Diagnostics) and urine creatinine was assayed using the modified Jaffé method (Colorimetric Assay, Roche, Diagnostics). Microalbuminuria was defined as a urine albumin to creatinine ratio (UACR) ≥17 mg/g in men and ≥25 mg/g in women. 31 
Clinical assessment
Systolic blood pressure was measured with a mercury sphygmomanometer on seated participants, and the mean of two readings was recorded for each individual. Weight in kilograms was divided by the square of height in metres to determine body mass index (BMI). Valvular heart disease was defined as a systolic murmur ≥3/6 in intensity or any diastolic murmur. We defined diabetes as fasting glucose ≥126 mg/dL, non-fasting glucose ≥200 mg/dL, or taking medications for the treatment of elevated glucose. Total and HDL-cholesterol were measured using standardized assays. Current smoking, antihypertensive treatment status, and history of myocardial infarction were ascertained by review of relevant medical records and patient questionnaires.
Echocardiography
Comprehensive two-dimensional transthoracic echocardiography with Doppler colour flow imaging was performed on all attendees of the sixth examination cycle of the Framingham Offspring study. Echocardiograms were read by a cardiologist or sonographer blinded to participants' clinical information. Measurements were made on digitized M-mode images using the leading edge-to-leading edge technique and were averaged over at least three cardiac cycles. This technique was used to measure left atrial dimension (LAD), LV septal wall thickness, LV posterior wall thickness, LV diameter at the end of diastole (LVEDD), and the LV diameter at the end of systole (LVESD). Fractional shortening (FS) was then calculated using the formula: [(LVEDD -LVESD)/LVEDD] × 100, and LV mass (LVM) was calculated as: 0.8{1.04[(LVEDD + posterior wall thickness + septal wall thickness) 3 -(LVEDD) 3 ]} + 0.6, based on American Society of Echocardiography guidelines. 32 Mild or greater reduction in LVEF based on qualitative assessment or FS <29% was used to define LV systolic dysfunction. LV hypertrophy (LVH) was determined by indexing LVM to body surface area, and values >115 g/m 2 for men and >95 g/m 2 for women were considered abnormal. 32 Left atrial enlargement (LAE) was defined as LAD >4.0 cm in men and >3.8 cm in women. 32 
Clinical assessment and outcome definitions
Participants in the FHS are under surveillance for cardiovascular outcomes, including hospitalized HF, which are ascertained after review of all medical records including physician visits and hospitalizations related to cardiovascular disease. Outcome events were adjudicated by a committee of three FHS physicians using the FHS criteria, 33 which define HF based on the presence of two major or one major and two minor criteria. Major criteria are paroxysmal nocturnal dyspnoea or orthopnoea, increased venous pressure, distended neck veins, rales, cardiomegaly by radiograph, pulmonary oedema, a third heart sound, hepatojugular reflux, and weight loss on diuretic therapy. Minor criteria include the presence of ankle oedema, nocturnal cough, hepatomegaly, dyspnoea on exertion, pleural effusion, decrease in vital capacity, and tachycardia. The FHS HF criteria are used in a wide variety of study settings and have been shown to have adequate sensitivity and specificity for the diagnosis of HF. 34, 35 Incident HF events occurring after 1980 (after imaging was more widely used) were adjudicated into HF subtypes using EF assessments by echocardiography, radionuclide angiography, or ventriculography during the index hospitalization or within 1 year prior to the onset of HF if no myocardial infarction occurred during the intervening period, as previously described. 24 Thus, LVEF assessment for adjudication of HF subtypes was based on imaging reports and medical records obtained at the time of HF hospitalization. These assessments of LV function were distinct from the echocardiograms systematically obtained at FHS study visits, which were used for cross-sectional analyses to examine cardiac structure and function in relation to kidney function measures prior to HF onset. HF events were classified as HFpEF if LVEF was >45%, and as HFrEF if LVEF was ≤45%.
Statistical analysis
Baseline characteristics for the samples were displayed according to the presence of CKD or microalbuminuria. Age-and sex-standardized incidence rates (by 10-year age strata) for HF and each HF subtype were calculated according to the presence of CKD or microalbuminuria with direct standardization using the internal study sample. To estimate the cumulative incidence of HFpEF and HFrEF, we used a Kaplan-Meier-like approach to account for competing risks of death, other HF subtype, and unclassified HF. 36 We used Cox proportional hazards regression models to assess the associations of eGFR and albuminuria with incident HF and HF subtypes after ensuring that the proportionality assumption was met. To account for correlated observations within individuals, we used robust sandwich covariance estimators. 37 The predictors included CKD (yes/no), eGFR (continuous, natural log-transformed), microalbuminuria (yes/no), and UACR (continuous, natural log-transformed). Models were adjusted for age and sex, and then additionally for smoking, BMI, total/HDL-cholesterol, diabetes, valvular heart disease, systolic blood pressure, hypertension treatment status, and history of myocardial infarction. For modelling the associations of the predictors with each HF subtype, we used the cause-specific method to account for the competing risks of death, other HF subtype, and of unclassified HF. In secondary analyses, we evaluated whether the associations of CKD and albuminuria with HF subtypes were modified by systolic blood pressure or diabetes status by introducing multiplicative interaction terms into the multivariable models.
. In cross-sectional analyses, we evaluated the associations between the same predictors [CKD, log(eGFR), microalbuminuria, and log(UACR)] and echocardiographic traits using multivariable-adjusted linear and logistic regression models. These models adjusted for age, sex, smoking, BMI, diabetes, valvular heart disease, systolic blood pressure, and hypertension treatment status.
We evaluated the association of two kidney function traits (CKD and microalbuminuria) with two main outcomes (HFpEF and HFrEF), and accordingly a Bonferroni corrected P-value of 0.0125 (0.05 divided by 4) was used to determine statistical significance for our prospective analyses, with a P-value of 0.0125-0.05 considered 'suggestive' of an association. For the echocardiographic analyses, we evaluated the association of the two kidney function traits with three main echocardiographic variables (systolic function, LVM/LVH, and left atrial size) and we therefore used a P-value of 0.008 to assess statistical significance. Analyses were performed using SAS Software version 9.3 (Cary, NC, USA).
Power calculations
With the observed event rates, and assuming that covariates explain 25% of the variance of our outcomes, the present investigation had 80% power to detect a hazard ratio (HR) of >1. 24 and >1.81 for the associations of HF subtypes with continuous eGFR and CKD, respectively. The power was 80% to detect a HR of >1.50 for continuous UACR and >2.16 for microalbuminuria.
Results
Baseline characteristics of the study samples by CKD and microalbuminuria status are displayed in Table 1 . The individuals with CKD were older, more likely to be women, had higher BMI and total cholesterol, and were more likely to have hypertension and diabetes, when compared with those without CKD. Among the 2912 participants included in the microalbuminuria analyses, 499 (17%) had microalbuminuria. When compared with participants without, individuals with microalbuminuria were older and more likely to have hypertension and diabetes.
Chronic kidney disease is associated with incident overall heart failure
Over a mean observation time of 13 ± 4 years, 598 (6.6%) individuals without CKD and 156 (17.2%) individuals with CKD developed incident HF. The age-and sex-standardized incidence rate of HF was nearly three-fold higher for those with CKD compared with those without CKD (17.4 vs. 5.9 events per 1000 person-years). Of 754 HF events, 324 (43%) were HFpEF, 326 (43%) HFrEF, and 104 (14%) were unclassified (baseline characteristics by HF subtype are shown in Supplementary material online, Table S1 ). Incidence rates of both HFpEF and HFrEF were higher among individuals with CKD compared with those without CKD, although rates of HFpEF and HFrEF appeared similar within the two groups (Table 2; Figure 1A ). Values represent the mean ± SD for continuous variables, except UACR, which is represented as median (25%, 75%), and number (%) for categorical variables. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; UACR, urinary albumin to creatinine ratio. In Cox regression models, the presence of CKD was associated with a 52% increased risk for HF in age-and sex-adjusted analyses [95% confidence interval (CI) 1.25-1.85, P < 0.0001], which was partially attenuated upon adjustment for clinical HF risk factors (HR 1.24, 95% CI 1.01-1.51, P = 0.04) ( Table 3) . CKD was not associated with incident HFpEF, but was associated with a 66% increased risk of HFrEF (95% CI 1.22-2.26, P = 0.001) in age-and sex-adjusted analyses, which did not reach statistical significance upon additional adjustment for clinical HF risk factors (HR 1.36, 95% CI 0.99-1.86, P = 0.06).
When examining eGFR as a continuous variable, we found similar associations. Each 1 SD higher log(eGFR) was associated with a 14% reduction in the risk of overall HF in age-and sex-adjusted analyses (95% CI 0.79-0.93, P = 0.006), but the association did not reach statistical significance after multivariable adjustment (HR 0.93, 95% CI 0.86-1.01, P = 0.08). Estimated GFR was inversely associated with the incidence of HFrEF [HR 0.83 for each 1 SD higher log(eGFR), 95% CI 0.73-0.95, P = 0.005] in age-and sex-adjusted analyses, which was not statistically significant upon multivariable adjustment (HR 0.90, 95% CI 0.80-1.02, P = 0.10).
. HFpEF was not significantly associated with eGFR in age-and sex-adjusted or multivariable-adjusted models ( Table 3) .
Microalbuminuria was associated with the incidence of overall heart failure and heart failure with reduced ejection fracion but not heart failure with preserved ejection fraction Figure 1B) . In multivariable-adjusted Cox models, we observed a more than two-fold higher risk of overall HF with microalbuminuria in age-and sex-adjusted analyses (HR 2.22, 95% CI 1.64-2.99, P < 0.0001). Microalbuminuria remained significantly associated with risk of overall HF after accounting for potential clinical confounders, including smoking, BMI, total/HDL-cholesterol, diabetes, valvular heart disease, systolic blood pressure, hypertension treatment, and history of myocardial infarction (HR 1.71, 95% CI 1.25-2.34, P < 0.0001) ( Table 3) . When examining HF subtypes, microalbuminuria was associated with incident HFpEF in age-and sex-adjusted (HR 1.62, 95% CI 1.02-2.55, P = 0.04) but not multivariable-adjusted models (HR 1.26, 95% CI 0.78-2.03, P = 0.34). In contrast, microalbuminuria was associated with an over two-fold increased risk of HFrEF in both age-and sex-adjusted (HR 2.89, 95% CI 1.89-4.41, P < 0.0001) and multivariable-adjusted (HR 2.10, 95% CI 1.35-3.26, P = 0.01) analyses.
When analysed as a continuous variable, UACR was associated with an increased risk of overall HF and both HF subtypes in ageand sex-adjusted and multivariable-adjusted analyses ( Table 3) .
Associations of chronic kidney disease and microalbuminuria with echocardiographic traits
We examined the cross-sectional associations of CKD with echocardiographic traits for 3075 participants with available eGFR and echocardiographic data (see Supplementary material online, Table S2 for baseline characteristics). CKD and reduced eGFR were not associated with LVM, LV systolic function, LVH, or LAE. A statistically significant association of higher eGFR with larger LAD (beta estimate for each 1 SD higher eGFR: 0.03 ± 0.01 cm, P = 0.005) was observed. Hazard ratios represent the relative hazard associated with having CKD or microalbuminuria, and the relative hazard associated with each 1 SD higher log-transformed eGFR and UACR. CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; HR, hazard ratio; UACR, urinary albumin to creatinine ratio. a Multivariable model is adjusted for age, sex, smoking, body mass index, total/HDL-cholesterol, diabetes, valvular heart disease, systolic blood pressure, hypertension treatment, and history of myocardial infarction.
In contrast, in the 2652 individuals with available echocardiographic data and UACR measured, UACR [odds ratio (OR) 1.48 for each 1 SD increase in UACR, 95% CI 1.14-1.90, P = 0.003] and microalbuminuria (OR 3.19, 95% CI 1.67-6.09, P = 0.0004) were associated with higher odds of having LV systolic dysfunction (Tables 4 and 5).
Secondary analyses
In secondary analyses, we tested for statistical interactions with systolic blood pressure and diabetes in the primary analyses. We found no evidence that the effect of CKD or microalbuminuria on either HF subtype was modified by diabetes or systolic blood pressure (P > 0.05 for all interactions).
In exploratory analyses, we formally tested for equality of the associations of CKD and microalbuminuria with incident HFrEF using the Lunn-McNeil technique. 38 The P-value for this test was 0.07 for the age-and sex-adjusted models and 0.13 for the multivariable model, and therefore the null hypothesis of equality was not rejected.
Discussion
In our community-based investigation, both CKD and microalbuminuria were associated with an increased risk of incident overall HF in adjusted analyses. When HF subtypes were examined separately, microalbuminuria was associated with a greater than two-fold increased risk of incident HFrEF but not HFpEF. Supporting our observation, we found that microalbuminuria (but not CKD) was associated with LV systolic dysfunction cross-sectionally. In contrast, CKD was not associated with either HF subtype in multivariable-adjusted models. Multiple studies have demonstrated that albuminuria predicts incident HF. 12, 13, 39, 40 In contrast, specific associations with HFrEF vs. HFpEF remain less clear. We observed a statistically significant association between baseline microalbuminuria and incident HFrEF but not HFpEF. In contrast to our findings, investigators from the PREVEND (Prevention of Renal and Vascular End-stage Disease) cohort showed that higher urinary albumin excretion was more strongly associated with incident HFpEF compared with HFrEF. 23 Several differences in study cohorts and design might account for the discrepant results between the PREVEND study and ours. In the present investigation, HFpEF and HFrEF each accounted for ∼50% of HF events; in PREVEND, 34% of events were characterized as HFpEF and 66% were HFrEF. The varying distribution in HF types might reflect inherent differences between the two study samples, including older mean age in PREVEND. Furthermore, the PREVEND cohort was designed to overselect individuals with elevated urinary albumin excretion, and, although statistical techniques were used to account for the probability of selection, this overselection might contribute to our discordant findings. The association of albuminuria with incident HFrEF was substantiated in our study by the association with LV systolic dysfunction cross-sectionally. Indeed, numerous previous studies have demonstrated associations of albuminuria with changes to cardiac structure and function including LV systolic dysfunction, higher LVM, and LVH. 41, 42 The mechanisms linking albuminuria with HF are not well elucidated. 41 However, because albuminuria is thought to reflect endothelial dysfunction and inflammation, 43 we may have expected stronger associations of albuminuria with HFpEF, which has been postulated to result from these conditions. 44 Our findings suggest Odds ratios represent the odds of having each binary echocardiographic trait for each 1 SD higher log-transformed eGFR and UACR, and for the presence of CKD and microalbuminuria vs. their absence. Analyses are adjusted for age, sex, smoking, body mass index, diabetes, valvular heart disease, systolic blood pressure, and hypertension treatment status. CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; OR, odds ratio; UACR, urinary albumin to creatinine ratio. that additional mechanisms may contribute to the increased risk of HF in those with albuminuria. As a marker of diffuse microvascular and endothelial injury, albuminuria may therefore serve as an indicator of similar end-organ changes in the heart. 45 Furthermore, albuminuria serves as a potent activator of the renin-angiotensin-aldosterone system, which is well known to contribute to the pathogenesis of HFrEF. The fact that inhibitors of the renin-angiotensin-aldosterone system (such as ACE inhibitors) both reduce albuminuria and improve HFrEF-related outcomes further supports a pathophysiological link. Our observed associations between CKD and incident overall HF are consistent with numerous previous reports. 7, 9, 10, 46, 47 Although several prior studies have examined the relationships of CKD (or reduced eGFR) with HFpEF vs. HFrEF, results have been conflicting. A report from the FHS similarly concluded that eGFR was not useful in predicting either HFpEF or HFrEF. 25 However, using a different sample of participants from the FHS, Lam et al. reported that higher serum creatinine was associated with incident HFrEF, but not HFpEF. 8 Concordantly, a retrospective study of mostly male veterans with clinical HF found that CKD was more common in patients with HFrEF than in those with HFpEF. 48 Conversely, using data from the PREVEND cohort, Brouwers et al. found higher cystatin C concentrations (another method of estimating glomerular filtration) to be associated with incident HFpEF, but not HFrEF. 23 Therefore, although reduced glomerular filtration (and CKD) was modestly associated with overall HF, whether it confers higher risk to either HF subtype remains unknown.
. Previous reports of associations of CKD with echocardiographic traits have been similarly inconsistent. Increased LVM is present in up to 40% of individuals with CKD, but whether this association persists after accounting for shared risk factors is controversial. 41 Whereas some studies have found independent associations between CKD and LVM, 49, 50 others have not. 51 Investigations evaluating the relationships between CKD and LVEF have consistently demonstrated no association, 41, 49, 51, 52 consistent with our findings. However, recent studies using more sensitive markers of LV systolic function, such as longitudinal strain imaging, have demonstrated more subtle abnormalities of LV systolic function to be present in HFpEF patients with CKD. 53 Although we did observe an association between eGFR and higher LAD (analysed as a continuous variable), no statistically significant association was observed between CKD (or eGFR) and LAE (analysed as a binary variable). The effect estimate for the observed association was small and the clinical relevance is therefore uncertain. Furthermore, LAD is a relatively crude measure of left atrial size, and future studies using left atrial volumetric assessments or measurements of left atrial function might be able to elucidate further relationships between CKD and left atrial size and function.
A number of mechanisms are likely to contribute to the observed association of CKD and incident HF. Cardiovascular and kidney disease share similar risk factors such as age, hypertension, diabetes, and obesity, and their joint impact on the heart and kidneys might partially explain the observed relationships. However, in our study, the associations between CKD and overall HF persisted even after accounting for these clinical risk factors, suggesting that other pathways are likely to be involved. CKD leads to volume retention, altered calcium-phosphate metabolism, hyperparathyroidism, vitamin D deficiency, anaemia, and the accumulation of uraemic toxins. These and other mechanisms related to reduced glomerular filtration may also contribute to the pathogenesis of overall HF, but the relative contributions to each HF subtype remain unknown.
Several limitations of the present investigation warrant mention. The adjudication of HFpEF and HFrEF was based on a single assessment of EF, which might lead to misclassification as EF (and therefore HF subtype) may change over time. Given our restricted power, meaningful associations with lower effect sizes cannot be definitively excluded. In particular, the formal testing of equality between the associations of CKD and microalbuminuria with incident HFrEF should be interpreted in the context of limited power when examining separate HF subtypes. Albuminuria and eGFR are commonly used but are relatively crude assessments of renal function; more sensitive measures of renal function could be used in future studies to explore our findings further. Furthermore, no EF assessment was available in ∼12% of individuals in the CKD sample and 4% in the microalbuminuria sample. As elderly individuals may be less likely to have EF assessed during a HF event, the unclassified individuals might be more likely to have HFpEF than HFrEF. Thus, ascertainment bias with regard to unclassified events might have influenced our findings. Our echocardiography analyses were limited to the measurements obtained at the sixth examination cycle of the Offspring cohort. Left atrial volumes and diastolic function were therefore unavailable. The study sample consisted of mostly white individuals of European descent, potentially limiting generalizability to other populations. Lastly, given the observational and post-hoc nature of this investigation, we cannot infer a causal relationship, nor can we rule out that residual confounding may be present. Notwithstanding these limitations, our study had several strengths. In particular, it was conducted in a large, community-based sample free of HF at study onset, with extensive long-term follow-up and systematic adjudication of EF.
In conclusion, both CKD and albuminuria were associated with incident overall HF in the community. Notably, albuminuria was more strongly associated with HFrEF compared with HFpEF, whereas CKD did not appear differentially associated with HF subtype. Our results suggest different pathogenic relationships linking mechanisms of kidney dysfunction with the development of HFrEF vs. HFpEF. Future studies are warranted to investigate the biological pathways involved in the association of albuminuria with HFrEF.
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